GeNeuro Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jesus Martin-Garcia

Chief Executive Officer (CEO)

€647.9k

Compensación total

Porcentaje del salario del CEO	67.1%
Permanencia del CEO	8.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	6yrs
Promedio de permanencia en la Junta Directiva	6.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jesus Martin-Garcia en comparación con los beneficios de GeNeuro?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€648k	€435k	-€15m
Sep 30 2023	n/a	n/a	-€14m
Jun 30 2023	n/a	n/a	-€13m
Mar 31 2023	n/a	n/a	-€13m
Dec 31 2022	€805k	€410k	-€12m
Sep 30 2022	n/a	n/a	-€11m
Jun 30 2022	n/a	n/a	-€9m
Mar 31 2022	n/a	n/a	-€8m
Dec 31 2021	€722k	€370k	-€7m
Sep 30 2021	n/a	n/a	-€8m
Jun 30 2021	n/a	n/a	-€8m
Mar 31 2021	n/a	n/a	-€9m
Dec 31 2020	€716k	€374k	-€9m
Sep 30 2020	n/a	n/a	-€9m
Jun 30 2020	n/a	n/a	-€9m
Mar 31 2020	n/a	n/a	-€9m
Dec 31 2019	€735k	€360k	-€9m
Sep 30 2019	n/a	n/a	-€10m
Jun 30 2019	n/a	n/a	-€10m
Mar 31 2019	n/a	n/a	-€9m
Dec 31 2018	€694k	€346k	-€8m
Sep 30 2018	n/a	n/a	-€4m
Jun 30 2018	n/a	n/a	-€192k
Mar 31 2018	n/a	n/a	-€3m
Dec 31 2017	€725k	€360k	-€6m

Compensación vs. Mercado: La compensación total de Jesus($USD674.73K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD471.14K).

Compensación vs. Ingresos: La compensación de Jesus ha sido consistente con los resultados de la empresa en el último año.

CEO

Jesus Martin-Garcia (62 yo)

8.8yrs

Permanencia

€647,944

Compensación

Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jesus Martin-Garcia	Chairman & CEO	8.8yrs	€647.94k	sin datos
Miguel Payró	Group Chief Financial Officer	9yrs	sin datos	sin datos
Hervé Perron	Chief Scientific Officer	no data	sin datos	sin datos
Alois Lang	Chief Development Officer	3.2yrs	sin datos	sin datos
Anke Post	Chief Medical Officer	less than a year	sin datos	sin datos

6.0yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GEM es experimentado (6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jesus Martin-Garcia	Chairman & CEO	18.8yrs	€647.94k	sin datos
Michel Dubois	Independent Director	16.3yrs	€12.90k	sin datos
Philippe Archinard	Independent Director	3.5yrs	sin datos	sin datos
Gordon Francis	Independent Director	9.7yrs	€17.20k	sin datos
Giacomo Di Nepi	Independent Director	9.3yrs	€12.90k	sin datos
Hedi Brahim	Independent Director	4.5yrs	sin datos	sin datos
Sandrine Flory	Independent Director	less than a year	sin datos	sin datos
Pascal Lemaire	Independent Director	less than a year	sin datos	sin datos

6.9yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de GEM se considera experimentada (6.9 años de antigüedad promedio).

GeNeuro Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Geneuro SA Announces Appointments of Board of Directors

Insufficient new directors

GeNeuro SA, Annual General Meeting, Jun 14, 2023

Insufficient new directors

Insufficient new directors

GeNeuro SA, Annual General Meeting, May 31, 2022

Recent updates

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

New minor risk - Financial data availability

Geneuro SA Announces Appointments of Board of Directors

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

New major risk - Negative shareholders equity

GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients

New major risk - Share price stability

GeNeuro SA to Report First Half, 2023 Results on Sep 29, 2023

Insufficient new directors

GeNeuro SA, Annual General Meeting, Jun 14, 2023

Insufficient new directors

GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab

Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms

GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis

Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes

Insufficient new directors

GeNeuro SA, Annual General Meeting, May 31, 2022

GeNeuro and Fondamental Foundation Announce the First Results of the Collaboration for the Development of Diagnostic and Therapeutic Options for Patients with Post-Covid Neuropsychiatric Syndromes

GeNeuro Announces the Completion of Its ProTEct-MS Study and Confirms the March Timeline for Top-line Results

Geneuro Sa unveils Additional Results from the Preclinical Research Program in Amyotrophic Lateral Sclerosis (Als) Developed in Partnership with the National Institute of Neurological Disorders and Stroke

Geneuro Receives EUR 6.4 Million in Funding from the Swiss Government for the Development of Temelimab Against Long-Covid

GeNeuro Announces First Patient Having Finished the ProTEct-MS Study at the Karolinska Institutet’s Academic Specialist Center Has Entered the Study Extension

Insufficient new directors

GeNeuro Announces the Publication in Multiple Sclerosis of Results From CHANGE-MS and ANGEL-MS Studies

Geneuro Presents Data Supporting Pathogenic Role of an Endogenous Retroviral Protein (HERV-W ENV) in Post-Covid Neuropsychiatric Syndrome

GeNeuro SA Announces Independent Drug Safety Monitoring Board (Dsmb) Has Concluded the Phase 2 Trial of Temelimab in Ms Patients

GeNeuro Completes Patient Recruitment in Temelimab Phase 2 Multiple Sclerosis Trial at the Karolinska Institutet’s Academic Specialist Center (ASC)

New 90-day high: €3.85

New 90-day low: €2.57

New 90-day low: €2.94

New 90-day low: €3.01

GeNeuro SA Announces Management Changes

GeNeuro SA to Report First Half, 2020 Results on Sep 29, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad